Followers | 1321 |
Posts | 26908 |
Boards Moderated | 6 |
Alias Born | 12/10/2012 |
Friday, January 27, 2023 9:53:43 AM
Letssssssssss goooooooooooooooooooooooooooo
https://www.newamsterdampharma.com/
Data presented at #ESCCongress and published in the European Heart Journal show "substantial individual variability in the LDL-c reduction" for patients on inclisiran, highlighting the need for new therapies that can reliably reduce LDL-c levels. https://t.co/7iGv7ESGl4 pic.twitter.com/KI22W5JRs2
— NewAmsterdam Pharma Corporation (@NewAmsPharma) January 24, 2023
$12 stop
GO $NAMS
Recent NAMS News
- NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results • GlobeNewswire Inc. • 05/09/2024 12:00:00 PM
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/03/2024 08:01:00 PM
- NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024 • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease • GlobeNewswire Inc. • 04/09/2024 12:00:00 PM
- NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer • GlobeNewswire Inc. • 04/01/2024 12:00:00 PM
- NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD • GlobeNewswire Inc. • 03/12/2024 12:00:00 PM
- NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/28/2024 01:00:00 PM
- NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants • GlobeNewswire Inc. • 02/14/2024 03:40:00 AM
- NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants • GlobeNewswire Inc. • 02/13/2024 09:01:00 PM
- NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference • GlobeNewswire Inc. • 02/01/2024 09:01:00 PM
- NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors • GlobeNewswire Inc. • 01/08/2024 01:00:00 PM
- NewAmsterdam Pharma Announces 2024 Strategic Priorities • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights • GlobeNewswire Inc. • 11/13/2023 01:00:00 PM
- NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer • GlobeNewswire Inc. • 10/23/2023 12:00:00 PM
- NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation • GlobeNewswire Inc. • 09/21/2023 11:00:00 AM
- NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference • GlobeNewswire Inc. • 09/20/2023 12:00:00 PM
- NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer • GlobeNewswire Inc. • 08/14/2023 08:01:00 PM
- NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights • GlobeNewswire Inc. • 08/07/2023 11:15:00 AM
- NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease • GlobeNewswire Inc. • 07/25/2023 08:01:00 PM
- NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares • GlobeNewswire Inc. • 06/09/2023 08:01:52 PM
- NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares • GlobeNewswire Inc. • 06/07/2023 03:25:53 AM
- NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary Shares • GlobeNewswire Inc. • 06/06/2023 08:01:00 PM
- NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients • GlobeNewswire Inc. • 06/05/2023 11:00:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM